摘要
溶瘤病毒的给药方式分瘤内注射和静脉注射。静脉注射溶瘤病毒可被免疫系统完全排除而不能发挥其抗肿瘤作用。应用具有淋巴细胞特性、干细胞特性、肿瘤细胞特性的细胞载体荷载并运输溶瘤病毒到达肿瘤部位发挥作用,可更好地发挥抗免疫/肿瘤效应。
Oncolytic viruses are intratumorally and intravenously administered.Oncolytic viruses delivered through intravenous injection trend to be eliminated by immune system and fail to exert anti-tumor activity.The anti-immune/tumor effect can be better exerted by cells having lymphocyte and stem cell characteristics and tumor cell characteristics,and transporting oncolytic virus to reach a tumor site.
作者
方敬敬
唐慧
FANG Jing-jing;TANG Hui(College of Medicine,Kunming University of Science and Technology,Kunming 650504;Yunnan Provincial Key Laboratory of Clinical Virology,Kunming Key Laboratory of Tumor Molecular&Immune Prevention,Institute of Basic Medical Sciences,Affiliated Hospital of Kunming University of Science and Technology,the First People s Hospital of Yunnan Province,Kunming 650032,China)
出处
《基础医学与临床》
CSCD
2018年第12期1761-1765,共5页
Basic and Clinical Medicine
基金
国家自然科学基金(81460463)
云南省中青年学术技术带头人后备人才培养基金(2013HB083)
云南省卫生和计划生育委员会医学学科带头人培养基金(D-201642)
关键词
细胞载体
溶瘤病毒
肿瘤治疗
cell carries
oncolytic virus
tumor therapy
